Literature DB >> 22694476

Nonmyeloablative conditioning generates autoantigen-encoding bone marrow that prevents and cures an experimental autoimmune disease.

Z Nasa1, J-Y Chung, J Chan, B-H Toh, F Alderuccio.   

Abstract

Autoimmune diseases result from chronic targeted immune responses that lead to tissue pathology and disease. The potential of autologous hematopoietic stem cells transplantation as a treatment for autoimmunity is currently being trialled but disease relapse is an issue. We have previously shown in a mouse model of experimental autoimmune encephalomyelitis (EAE) that the transplantation of bone marrow (BM) transduced to encode the autoantigen myelin oligodendrocyte glycoprotein (MOG) can prevent disease induction. However these studies were performed using lethal irradiation to generate BM chimeras and a critical factor for translation to humans would be the ability to utilize low toxic preconditioning regimes. In this study, treosulfan was used as a nonmyeloablative agent to generate BM chimeras encoding MOG and assessed in models of EAE induction and reversal. We find that treosulfan conditioning can promote a low degree of chimerism that is sufficient to promote antigen specific tolerance and protect mice from EAE. When incorporated into a curative protocol for treating mice with established EAE, nonmyeloablative conditioning and low chimerism was equally efficient in maintaining disease resistance. These studies further underpin the potential and feasibility of utilizing a gene therapy approach to treat autoimmune disease. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694476     DOI: 10.1111/j.1600-6143.2012.04068.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

2.  Tackling autoimmunity with gene therapy.

Authors:  Frank Alderuccio; Ban-Hock Toh
Journal:  Chimerism       Date:  2012-07-01

Review 3.  Re-educating immunity in respiratory allergies: the potential for hematopoietic stem cell-mediated gene therapy.

Authors:  Jeremy F Brooks; Janet M Davies; James W Wells; Raymond J Steptoe
Journal:  J Mol Med (Berl)       Date:  2017-11-17       Impact factor: 4.599

4.  Development of Gene Transfer for Induction of Antigen-specific Tolerance.

Authors:  Brandon K Sack; Roland W Herzog; Cox Terhorst; David M Markusic
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-30       Impact factor: 6.698

5.  Bone Marrow-Derived Cell Accumulation in the Spinal Cord Is Independent of Peripheral Mobilization in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Kyle Peake; John Manning; Coral-Ann Lewis; Kevin Tran; Fabio Rossi; Charles Krieger
Journal:  Front Neurol       Date:  2017-03-08       Impact factor: 4.003

6.  Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up.

Authors:  Ana C Londoño; Carlos A Mora
Journal:  J Clin Cell Immunol       Date:  2016-09-20

Review 7.  The Immune Response to the fVIII Gene Therapy in Preclinical Models.

Authors:  Seema R Patel; Taran S Lundgren; H Trent Spencer; Christopher B Doering
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

Review 8.  Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.

Authors:  Judith Derdelinckx; Patrick Cras; Zwi N Berneman; Nathalie Cools
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.